Regulatory PathRegulatory requirements compared

Active substance

Tolnaftate

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade nameStrengthForm · routePackPublic priceTypeCompanyStatus
TINADERM SOLUTION 1%1 %Solution · Topical1 BottleSAR 8.55NCE · OTCSCHERING-PLOUGHWithdrawn by MAH · Not Marketed
TINEA CURE PAINT 1%1 %Cutaneous liquid · Topical1 BottleSAR 5.50NCE · OTCKAHIRA EYGEPTWithdrawn by regulatory authority · Not Marketed
TINEACURE CREAM1 %Cream · Topical1 TubeSAR 5.15NCE · OTCKAHIRA EYGEPTWithdrawn by regulatory authority · Not Marketed

Canada Canada — marketed products (Health Canada)

BrandDINStrengthForm · routeCompany
ATHLETE'S FOOT CREAM025611821 % / W/WCREAM · TOPICALSCHOLL'S WELLNESS COMPANY
DR. SCHOLL'S ATHLETE'S FOOT SPRAY POWDER019192451 % / W/WAEROSOL; POWDER · TOPICALSCHOLL'S WELLNESS COMPANY
FLEXITOL MEDICATED ANTI-FUNGAL CREAM022958731 %CREAM · TOPICALLACORIUM HEALTH INTERNATIONAL PTY LTD.
FOOTRENEW025277231 % / W/WSOLUTION · TOPICALNAILRENEW CORP.
FORMULA 3024137601 % / W/WSOLUTION · TOPICALTHE TETRA CORPORATION
ODOR-EATERS022447771 % / W/WAEROSOL · TOPICALBLISTEX CORPORATION
TINACTIN005760341 % / W/WCREAM · TOPICALBAYER INC
TINACTIN AEROSOL POWDER005760501 % / W/WAEROSOL; POWDER · TOPICALBAYER INC
TINACTIN CHILL DEODORANT POWDER SPRAY023192761 % / W/WPOWDER; AEROSOL · TOPICALBAYER INC
TINACTIN CHILL LIQUID SPRAY023193141 %AEROSOL · TOPICALBAYER INC
TINACTIN POWDER005760421 % / W/WPOWDER · TOPICALBAYER INC
TOLNAFTATE CREAM USP, 1%022267071 %CREAM · TOPICALTARO PHARMACEUTICALS INC

Prices — United States and England

SourceProduct as listedPriceUnit / packDate
US NADACTOLNAFTATE 1% CREAM$0.09038per GM23 Sep 2026
US NADACTOLNAFTATE 1% CREAM$0.11888per GM23 Sep 2026
US NADACTOLNAFTATE 1% CREAM$0.15per GM23 Sep 2026
US NADACTOLNAFTATE 1% POWDER$0.04296per GM19 Nov 2025
NHS Drug TariffTolnaftate 1% liquid spray£4.52150 ml1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.